Filing Details

Accession Number:
0000899243-22-012990
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-31 20:15:26
Reporting Period:
2022-03-29
Accepted Time:
2022-03-31 20:15:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1880438 An2 Therapeutics Inc. ANTX () E9
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1783165 Adjuvant Global Health Technology Fund, L.p. C/O Adjuvant Capital, L.p.
501 Fifth Avenue, Suite 1404
New York NY 10017
No No Yes No
1799812 Adjuvant Global Health Technology Fund De, L.p. C/O Adjuvant Capital, L.p.
501 Fifth Avenue, Suite 1404
New York NY 10017
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-29 1,651,636 $0.00 1,651,636 No 4 C Indirect By Adjuvant Global Health Technology Fund, L.P.
Common Stock Acquisiton 2022-03-29 312,415 $0.00 312,415 No 4 C Indirect By Adjuvant Global Health Technology Fund DE, L.P.
Common Stock Acquisiton 2022-03-29 392,433 $0.00 2,044,069 No 4 C Indirect By Adjuvant Global Health Technology Fund, L.P.
Common Stock Acquisiton 2022-03-29 74,230 $0.00 386,645 No 4 C Indirect By Adjuvant Global Health Technology Fund DE, L.P.
Common Stock Acquisiton 2022-03-29 166,666 $15.00 2,210,735 No 4 P Indirect By Adjuvant Global Health Technology Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Adjuvant Global Health Technology Fund, L.P.
No 4 C Indirect By Adjuvant Global Health Technology Fund DE, L.P.
No 4 C Indirect By Adjuvant Global Health Technology Fund, L.P.
No 4 C Indirect By Adjuvant Global Health Technology Fund DE, L.P.
No 4 P Indirect By Adjuvant Global Health Technology Fund, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2022-03-29 1,651,636 $0.00 1,651,636 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2022-03-29 312,415 $0.00 312,415 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2022-03-29 392,433 $0.00 392,433 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2022-03-29 74,230 $0.00 74,230 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
  2. Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
  3. Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.